AI주식인사이트AI Stock Insight
C

싸이토젠

217330KOSDAQ

48.0 / 100

Reference Date: 2026-10-23

Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 11.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

CytoGen focuses on liquid biopsy platforms based on CTC (Circulating Tumor Cells) technology, offering services such as supporting anti-cancer drug development, precision medicine, and health supplement sales. Key business areas include companion diagnostics development with pharmaceutical companies, medical device distribution, and health supplement sales, while also expanding globally through research and international collaborations.

Number of Employees

39people

Average Salary

64.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.70Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-29.06Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
31.95Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲190.7% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲16.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -38.7% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,645Won52-week high 9,42052-week low 2,615
1-month return1.0Point

1m -11.83% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 1Neutral 4Negative 0
  • Positive[기재정정]단일판매ㆍ공급계약체결(자율공시)2026-10-20
  • Neutral주식등의대량보유상황보고서(일반)2026-10-12
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-12
  • Neutral주식등의대량보유상황보고서(일반)2026-10-12
  • Neutral합병등종료보고서(합병)2026-10-01